STOCK TITAN

Vaxcyte, Inc. (PCVX) director files Form 3 reporting zero holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Vaxcyte, Inc. director Markels John filed an initial Form 3 reporting his beneficial ownership. The report states that he owns no Vaxcyte securities, with total direct holdings of 0 shares following the reported position. No purchases, sales, or derivative or option positions are disclosed.

Positive

  • None.

Negative

  • None.
Insider Markels John
Role Director
Type Security Shares Price Value
holding No securities owned. -- -- --
Holdings After Transaction: No securities owned. — 0 shares (Direct)
Footnotes (1)
Shares owned after reporting 0.0000 shares Total direct holdings following the Form 3 entry
Reported buy transactions 0 buyCount in transaction summary
Reported sell transactions 0 sellCount in transaction summary
Holding entries reported 1 holdingEntries in transaction summary
Form 3 regulatory
"Markels John filed an initial Form 3 reporting his beneficial ownership"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership financial
"filed an initial Form 3 reporting his beneficial ownership"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
reporting person regulatory
"The Form 3 identifies the reporting person as a director"
derivative positions financial
"No purchases, sales, or derivative positions are disclosed"
Derivative positions are contracts that derive their value from an underlying asset—such as a stock, bond, currency or commodity—and include instruments like options, futures and swaps. Think of them as bets or insurance tied to an asset’s future price: they let investors amplify returns, hedge risk or take exposure without owning the asset directly, which can meaningfully increase potential gains, losses and volatility in a portfolio.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does the Form 3 filed by Markels John mean for Vaxcyte (PCVX)?

The Form 3 shows that director Markels John reports owning no Vaxcyte shares. It is an initial statement of beneficial ownership, indicating his reported starting position as a director is zero, with no accompanying purchases, sales, or derivative holdings disclosed.

Does the Vaxcyte (PCVX) director Markels John own any company stock?

According to the Form 3, director Markels John owns 0 Vaxcyte shares. The filing lists “No securities owned” and reports total direct holdings of 0.0000 shares following the report, with no other equity or derivative interests shown.

Were any stock transactions reported in this Vaxcyte (PCVX) Form 3?

No transactions were reported; the Form 3 is a holding-only entry. The transaction section simply records that no securities are owned, with buyCount, sellCount, and exerciseCount all at 0, and one holding entry reflecting zero shares.

Does Markels John hold any options or derivatives in Vaxcyte (PCVX)?

The Form 3 shows no derivative positions for Markels John. The derivativeSummary is empty and derivativeTransactionCount is 0, indicating no reported options, warrants, or other derivative securities linked to Vaxcyte common stock.

What role does Markels John have at Vaxcyte (PCVX) in this Form 3?

The Form 3 identifies Markels John as a director of Vaxcyte, Inc. He is not listed as an officer and is not reported as a ten percent owner, and his initial statement reports zero beneficial ownership of company securities.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Markels John

(Last)(First)(Middle)
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, SUITE 300

(Street)
SAN CARLOS CALIFORNIA 94070

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
07/16/2026
3. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities owned.0D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
Remarks:
John Markels, by /s/ Peter N. Efremenko, Attorney-In-Fact07/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)